A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Overview

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

Full Title of Study: “Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2″

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 31, 2022

Detailed Description

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

Interventions

  • Drug: RC48-ADC
    • RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks
  • Drug: Paclitaxel Injection
    • Administered according to label, as one option for Physician’s Choice (determined before randomization)
  • Drug: Docetaxel Injection
    • Administered according to label, as one option for Physician’s Choice (determined before randomization)
  • Drug: Vinorelbine Tartrate Injection
    • Administered according to label, as one option for Physician’s Choice (determined before randomization)
  • Drug: Capecitabine Tablets
    • Administered according to label, as one option for Physician’s Choice (determined before randomization)

Arms, Groups and Cohorts

  • Experimental: RC48-ADC
    • RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.
  • Active Comparator: Physician’s Choice
    • Physician’s Choice: HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis. Physician’s choice from the following options: Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets

Clinical Trial Outcome Measures

Primary Measures

  • Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
    • Time Frame: within approximately 3 years
    • Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher’s evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

Secondary Measures

  • Progression-free survival (PFS), evaluated by the investigator
    • Time Frame: within approximately 3 years
    • Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher’s evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.
  • Objective remission rate (ORR)
    • Time Frame: within approximately 3 years
    • The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).
  • Duration of relief (DOR)
    • Time Frame: within approximately 3 years
    • DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death
  • Disease control rate (DCR)
    • Time Frame: within approximately 3 years
    • Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.
  • Tumor progression time (TTP)
    • Time Frame: within approximately 3 years
    • Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).
  • Overall survival (OS)
    • Time Frame: within approximately 3 years
    • Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

Participating in This Clinical Trial

Inclusion Criteria

  • Voluntarily agree to participate in the study and sign the informed consent;
  • Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
  • For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
  • Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
  • Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

  • Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

  • Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

  • Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

  • Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
  • The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
  • Previous use of anthracycline drugs;
  • Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
  • Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for first-line endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
  • The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
  • There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
  • Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria

  • Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
  • The research drug was used within 4 weeks before the start of study administration;
  • Have undergone major surgery within 4 weeks before the start of study administration;
  • Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
  • Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
  • Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
  • There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
  • Suffering from active infection requiring systemic treatment;
  • Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
  • The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
  • Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
  • Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
  • There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
  • Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
  • Subjects who are not suitable for using any of the alternative control drugs;
  • The presence of brain metastases and / or cancerous meningitis;
  • Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
  • Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • RemeGen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Binghe Xu, Principal Investigator, Chinese Academy of Medical Sciences
    • Tao Sun, Principal Investigator, Liaoning Tumor Hospital & Institute
    • Wei Li, Principal Investigator, First Hospital of Jilin University
    • Yuee Teng, Principal Investigator, First Hospital of China Medical University
    • Shu Wang, Principal Investigator, Peking University People’s Hospital
    • Xiaojia Wang, Principal Investigator, Zhejiang Cancer Hospital
    • Xichun Hu, Principal Investigator, Fudan University
    • Min Yan, Principal Investigator, Henan Cancer Hospital
    • Jifeng Feng, Principal Investigator, Jiangsu Cancer Institute & Hospital
    • Ying Cheng, Principal Investigator, Jilin Provincial Tumor Hospital
    • Ying Wang, Principal Investigator, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    • Shusen Wang, Principal Investigator, Cancer prevention and treatment center, sun yat-sen university
    • Ning Liao, Principal Investigator, Guangdong Provincial People’s Hospital
    • Haibo Wang, Principal Investigator, Affiliated Hospital of Qingdao University
    • Quchang OuYang, Principal Investigator, Hunan Cancer Hospital
    • Yueyin Pan, Principal Investigator, Anhui Provincial Hospital
    • Yingying Du, Principal Investigator, The First Affiliated Hospital of Anhui Medical University
    • Changlu Hu, Principal Investigator, Anhui Cancer Hospital
    • Zhongsheng Tong, Principal Investigator, Tianjin Cancer Hospital
    • Jin Yang, Principal Investigator, The First Affiliated Hospital of Xi’an Jiaotong University School of Medicine
    • Lihua Song, Principal Investigator, Shandong Cancer Hospital
    • Xiuwen Wang, Principal Investigator, Qilu Hospital of Shandong University
    • Yu Jiang, Principal Investigator, West China Hospital
    • Yunjiang Liu, Principal Investigator, The Fourth Hospital of Hebei Medical University
    • Jing Cheng, Principal Investigator, Wuhan Union Hospital, China
    • Huihua Xiong, Principal Investigator, Huazhong University of Science Tongji Hospital, Tongji Medical College
    • Xinhong Wu, Principal Investigator, Hubei Cancer Hospital
    • Peng Shen, Principal Investigator, First Affiliated Hospital of Zhejiang University School of Medicine
    • Weimin Xie, Principal Investigator, Cancer Hospital Affiliated to Guangxi Medical University
    • Xin Zhou, Principal Investigator, Chongqing University Cancer Hospital
    • Li Ran, Principal Investigator, Cancer Hospital of Guizhou Province
    • Yu Wang, Principal Investigator, Shanxi Province Cancer Hospital
    • Jinnan Gao, Principal Investigator, Bethune Hospital of Shanxi Province
    • Jingfen Wang, Principal Investigator, Linyi Cancer Hospital
    • Liangmin Zhang, Principal Investigator, Yantai Yuhuangding Hospital
    • Xianhe Xie, Principal Investigator, First Affiliated Hospital of Fujian Medical University
    • Ru Zeng, Principal Investigator, The First Affiliated Hospital of Xiamen University
    • Airong Wang, Principal Investigator, Weihai Municipal Hospital
    • Zhengqiu Zhu, Principal Investigator, Affiliated Hospital of Xuzhou Medical University
    • Sanyuan Sun, Principal Investigator, Xuzhou Central Hospital
    • Qingshan Li, Principal Investigator, Affiliated Hospital of Chengde Medical College
    • Aimin Zang, Principal Investigator, Affiliated Hospital of Hebei University
    • Liuzhong Yang, Principal Investigator, The First Affiliated Hospital of Xinxiang Medical College
    • Yuping Sun, Principal Investigator, Jinan Central Hospital
    • Liang Li, Principal Investigator, Zibo Central Hospital
    • Guohua Yu, Principal Investigator, Weifang People’s Hospital
    • Xujuan Wang, Principal Investigator, Neijiang Second People’s Hospital
  • Overall Contact(s)
    • Binghe Xu, M.D., 010-87788826, bhxu@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.